Back to Search
Start Over
Chemotherapeutics for Acute Erythroid Leukemia: Research, Present and Future
- Source :
- Current Molecular Medicine. 21:819-831
- Publication Year :
- 2021
- Publisher :
- Bentham Science Publishers Ltd., 2021.
-
Abstract
- Acute erythroid leukemia (AEL) is a subtype of acute myeloid leukemia (AML) with features such as accumulation of maturation-arrested erythroblasts. Compared with AML, the progression of AEL is faster and the prognosis to available therapy is worse. However, its categorization is still being updated and the pathophysiology of AEL is still under research, making diagnosis and chemotherapy challenging for physicians. To achieve better outcomes, therapies should be optimized and new drugs should be developed. In this review, we summarize current strategies of diagnosis and therapies of AEL, and discuss prospective targets for chemotherapeutic agents based on the biological characteristics of AEL neoplastic cells as well as transcriptional factors and pathways related to erythroid differentiation.
- Subjects :
- Chemotherapy
business.industry
medicine.medical_treatment
Acute erythroid leukemia
Myeloid leukemia
Cell Differentiation
General Medicine
medicine.disease
Biochemistry
Neoplasm Proteins
hemic and lymphatic diseases
Mutation
Cancer research
Humans
Molecular Medicine
Medicine
Leukemia, Erythroblastic, Acute
business
Molecular Biology
Transcription Factors
Subjects
Details
- ISSN :
- 15665240
- Volume :
- 21
- Database :
- OpenAIRE
- Journal :
- Current Molecular Medicine
- Accession number :
- edsair.doi.dedup.....8a5f1ea9511ea150de52d3d51fba3c4b